Skip to content

Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections

Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections: A Multicentre Study Using Target Trial Emulation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07593547
Acronym
EMULATE-Sm
Enrollment
790
Registered
2026-05-18
Start date
2026-03-06
Completion date
2026-12-31
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloodstream Infection, Pneumonia - Bacterial, S Maltophilia Infections

Keywords

S. maltophilia, Infection, Mortality, Combined therapy

Brief summary

The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is: • Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections? Researchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.

Interventions

None listed

Sponsors

Instituto de Investigación Sanitaria Gregorio Marañón
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients * S. maltophilia infections * Different episodes if a new infection ocurred \> 30 days since the index episode

Exclusion criteria

* isolates obtained from patients outside of hospital admission * microbiological or clinical colonization * hospitalizations shorter than 72 hours since the time zero * patients who died in the first 72 hours since the time zero or who were in imminent risk of death * polymicrobial infections * receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours * absence of data outcomes

Design outcomes

Primary

MeasureTime frame
All-cause mortalityAt 30 days

Secondary

MeasureTime frameDescription
Frequency of complicationsAt 60 daysneed for ICU admission and/or RRT, ECMO, recurrences, or in-hospital readmissions
Frequency of adverse eventsAt 60 days

Countries

Spain

Contacts

CONTACTSofia de la villa Martinez, MD
sofiadela.villa@salud.madrid.org+3491868453

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026